Technical paper: Low risk frozen distribution of SU bags for bioprocessing
Posted: 20 December 2021 | Entegris | No comments yet
This paper discusses the results of a study that help to mitigate the risks during frozen shipping and ensure consistent product quality in cold chain.
The ongoing race to develop treatments for COVID-19 requires a temperature-controlled distribution network that can quickly scale-up to meet huge demands.
This paper provides guidelines:
- to employ sensors for monitoring critical shipment parameters
- on utilisation of more suitable low-temperature materials and packaging
- for qualification and evaluation through simulated standards and testing real-world transit lanes.
Implementing these guidelines will ensure consistent product quality in cold chain.
Related content from this organisation
- ebook: A practical guide to single-use filtration in biopharma
- Biologics driving continuous bioprocessing market expansion
- On-demand webinar: Risk mitigation for single-use cold chain distribution
- Technical paper: Low risk frozen distribution of SU bags for bioprocessing
- Application note: Resilient plastics in the Cold Chain
Related topics
Biologics, Biopharmaceuticals, Bioprocessing, Biosimilars, Drug Delivery Systems, Freeze Drying, Gene therapy, Manufacturing, QA/QC, Research & Development (R&D), Stem Cells, Supply Chain, Vaccines
